{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:22:06Z","timestamp":1783009326588,"version":"3.54.5"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:00:00Z","timestamp":1760745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:00:00Z","timestamp":1760745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychiatr Q"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s11126-025-10205-y","type":"journal-article","created":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T11:48:30Z","timestamp":1760788110000},"page":"463-482","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of Curcumin Supplementation on Schizophrenia Treatment: A Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1007","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1484-4581","authenticated-orcid":false,"given":"Mariano","family":"Gallo Ruelas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1368-1130","authenticated-orcid":false,"given":"Fernanda Ribeiro","family":"de Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8099-7554","authenticated-orcid":false,"given":"Giovanna Hanike Santos","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4358-0139","authenticated-orcid":false,"given":"Carla Manuella Campelo Guerra Queir","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1032-0828","authenticated-orcid":false,"given":"Daniele Fernandes","family":"Holanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,18]]},"reference":[{"key":"10205_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.schres.2009.03.005","volume":"110","author":"R Tandon","year":"2009","unstructured":"Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, \u2018just the facts\u2019 4. Clinical features and conceptualization. Schizophr Res. 2009;110:1\u201323.","journal-title":"Schizophr Res"},{"key":"10205_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","volume":"373","author":"S Leucht","year":"2009","unstructured":"Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet Lond Engl. 2009;373:31\u201341.","journal-title":"Lancet Lond Engl"},{"key":"10205_CR3","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/S0140-6736(17)30060-0","volume":"389","author":"G N\u00e9meth","year":"2017","unstructured":"N\u00e9meth G, Laszlovszky I, Czobor P, Szalai E, Szatm\u00e1ri B, Hars\u00e1nyi J, et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet. 2017;389:1103\u201313.","journal-title":"Lancet"},{"key":"10205_CR4","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/wps.20516","volume":"17","author":"CU Correll","year":"2018","unstructured":"Correll CU, Rubio JM, Kane JM. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry. 2018;17:149\u201360.","journal-title":"World Psychiatry"},{"key":"10205_CR5","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.euroneuro.2014.03.008","volume":"24","author":"MJ Millan","year":"2014","unstructured":"Millan MJ, Fone K, Steckler T, Horan WP. Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. Eur Neuropsychopharmacol. 2014;24:645\u201392.","journal-title":"Eur Neuropsychopharmacol"},{"key":"10205_CR6","unstructured":"Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia | Minerva Neurosciences, Inc. [Internet]. [cited 2025 July 14]. Available from: https:\/\/ir.minervaneurosciences.com\/news-releases\/news-release-details\/minerva-neurosciences-receives-complete-response-letter-fda-new."},{"key":"10205_CR7","doi-asserted-by":"crossref","unstructured":"Arnovitz MD, Spitzberg AJ, Davani AJ, Vadhan NP, Holland J, Kane JM, et al. MDMA for the treatment of negative symptoms in Schizophrenia. J Clin Med [Internet]. 2022 [cited 2025 July 14];11:3255. Available from: https:\/\/www.mdpi.com\/2077-0383\/11\/12\/3255.","DOI":"10.3390\/jcm11123255"},{"key":"10205_CR8","doi-asserted-by":"crossref","unstructured":"Correll CU, Schooler NR. Negative symptoms in Schizophrenia: a review and clinical guide for recognition, assessment, and treatment. Neuropsychiatr Dis Treat [Internet]. 2020 [cited 2025 July 15];16:519\u201334. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7041437\/.","DOI":"10.2147\/NDT.S225643"},{"key":"10205_CR9","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s00127-023-02556-3","volume":"59","author":"GP Strauss","year":"2024","unstructured":"Strauss GP. Environmental factors contributing to negative symptoms in youth at clinical high risk for psychosis and outpatients with schizophrenia. Soc Psychiatry Psychiatr Epidemiol. 2024;59:1167\u201375. https:\/\/doi.org\/10.1007\/s00127-023-02556-3.","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"10205_CR10","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/j.1600-0447.1995.tb09599.x","volume":"92","author":"JM Ca\u00f1iv\u00e9","year":"1995","unstructured":"Ca\u00f1iv\u00e9 JM, Sanz-Fuentenebro J, V\u00e1zquez C, Qualls C, Fuentenebro F, Tuason VB. Family environment predictors of outcome in schizophrenic patients in Spain: a nine-month follow-up study. Acta Psychiatr Scand. 1995;92:371\u20137.","journal-title":"Acta Psychiatr Scand"},{"key":"10205_CR11","first-page":"99","volume":"13","author":"WK Halford","year":"1991","unstructured":"Halford WK. Beyond expressed emotion: behavioral assessment of family interaction associated with the course of schizophrenia. Behav Assess. 1991;13:99\u2013123.","journal-title":"Behav Assess"},{"key":"10205_CR12","doi-asserted-by":"crossref","unstructured":"Foussias G, Agid O, Fervaha G, Remington G. Negative symptoms of schizophrenia: Clinical features, relevance to real world functioning and specificity versus other CNS disorders. Eur Neuropsychopharmacol [Internet]. 2014 [cited 2025 July 15];24:693\u2013709. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0924977X1300326X.","DOI":"10.1016\/j.euroneuro.2013.10.017"},{"key":"10205_CR13","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00213-008-1300-y","volume":"201","author":"SK Kulkarni","year":"2008","unstructured":"Kulkarni SK, Bhutani MK, Bishnoi M. Antidepressant activity of curcumin: involvement of serotonin and dopamine system. Psychopharmacology. 2008;201:435\u201342.","journal-title":"Psychopharmacology"},{"issue":"3","key":"10205_CR14","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1177\/0269881116686883","volume":"31","author":"AL Lopresti","year":"2017","unstructured":"Lopresti AL. Curcumin for neuropsychiatric disorders: a review of in vitro, animal and human studies. J Psychopharmacol. 2017;31(3):287\u2013302. https:\/\/doi.org\/10.1177\/0269881116686883.","journal-title":"J Psychopharmacol"},{"key":"10205_CR15","unstructured":"Hewlings SJ, Kalman DS. Curcumin: a review of its\u2019 effects on human health. Foods [Internet]. 2017 [cited 2024 July 13];6:92. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5664031\/."},{"key":"10205_CR16","doi-asserted-by":"crossref","unstructured":"Lamanna-Rama N, Romero-Miguel D, Desco M, Soto-Montenegro ML. An update on the exploratory use of curcumin in neuropsychiatric disorders. Antioxidants [Internet]. 2022 [cited 2024 Oct 23];11:353. Available from: https:\/\/www.mdpi.com\/2076-3921\/11\/2\/353.","DOI":"10.3390\/antiox11020353"},{"key":"10205_CR17","doi-asserted-by":"crossref","unstructured":"Dinakaran D, Sreeraj VS, Venkatasubramanian G. Role of curcumin in the management of Schizophrenia: a narrative review. Indian J Psychol Med [Internet]. 2021 [cited 2024 Oct 23];44:107. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9120991\/.","DOI":"10.1177\/02537176211033331"},{"issue":"3","key":"10205_CR18","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s11064-022-03798-4","volume":"48","author":"R Rabiee","year":"2023","unstructured":"Rabiee R, Hosseini Hooshiar S, Ghaderi A, Jafarnejad S. Schizophrenia, curcumin and minimizing side effects of antipsychotic drugs: possible mechanisms. Neurochem Res. 2023;48(3):713\u201324. https:\/\/doi.org\/10.1007\/s11064-022-03798-4.","journal-title":"Neurochem Res"},{"key":"10205_CR19","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ [Internet]. 2021 [cited 2024 Mar 2];n71. Available from: https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj.n71.","DOI":"10.1136\/bmj.n71"},{"key":"10205_CR20","unstructured":"Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions [Internet]. 2020 [cited 2024 Mar 2]. Available from: https:\/\/training.cochrane.org\/handbook."},{"key":"10205_CR21","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.schres.2017.09.046","volume":"195","author":"JK Wynn","year":"2018","unstructured":"Wynn JK, Green MF, Hellemann G, Karunaratne K, Davis MC, Marder SR. The effects of curcumin on brain-derived neurotrophic factor and cognition in schizophrenia: a randomized controlled study. Schizophr Res. 2018;195:572\u20133.","journal-title":"Schizophr Res"},{"key":"10205_CR22","unstructured":"RoB 2: A revised Cochrane risk-of-bias tool for randomized trials | Cochrane Bias [Internet]. [cited 2024 Mar 2]. Available from: https:\/\/methods.cochrane.org\/bias\/resources\/rob-2-revised-cochrane-risk-bias-tool-randomized-trials."},{"key":"10205_CR23","unstructured":"Sch\u00fcnemann H, Bro\u017cek J, Guyatt G, Oxman A. GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013 [Internet]. The GRADE Working Group; 2013 [cited 2024 Oct 26]. Available from: https:\/\/www.guidelinedevelopment.org\/handbook."},{"key":"10205_CR24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1164","volume":"7","author":"AA Veroniki","year":"2016","unstructured":"Veroniki AA, Jackson D, Viechtbauer W, Bender R, Bowden J, Knapp G, et al. Methods to estimate the between-study variance and its uncertainty in meta-analysis. Res Synth Methods. 2016;7:55\u201379.","journal-title":"Res Synth Methods"},{"key":"10205_CR25","unstructured":"Deeks J, Higgins J, Altman D. Chapter 10: Analysing data and undertaking meta-analyses. Cochrane Handbook for Systematic Reviews of Interventions version 6.4 [Internet]. Cochrane, 2023.; [cited 2024 Oct 26]. Available from: www.training.cochrane.org\/handbook."},{"key":"10205_CR26","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/WNF.0000000000000344","volume":"42","author":"C Miodownik","year":"2019","unstructured":"Miodownik C, Lerner V, Kudkaeva N, Lerner PP, Pashinian A, Bersudsky Y, et al. Curcumin as add-on to antipsychotic treatment in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol. 2019;42:117\u201322.","journal-title":"Clin Neuropharmacol"},{"key":"10205_CR27","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1097\/JCP.0000000000001012","volume":"39","author":"S Kucukgoncu","year":"2019","unstructured":"Kucukgoncu S, Guloksuz S, Tek C. Effects of curcumin on cognitive functioning and inflammatory state in schizophrenia: a double-blind, placebo-controlled pilot trial. J Clin Psychopharmacol. 2019;39:182\u20134.","journal-title":"J Clin Psychopharmacol"},{"key":"10205_CR28","doi-asserted-by":"crossref","unstructured":"Hosseininasab, Masumeh. Nanocurcumin as an add-on to antipsychotic drugs for treatment of negative symptoms in patients with chronic Schizophrenia: a randomized, double-blind, placebo-controlled study - PubMed. J Clin Psychopharmacol [Internet]. 2021 [cited 2024 June 26];41:25\u201330. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33347019\/.","DOI":"10.1097\/JCP.0000000000001324"},{"key":"10205_CR29","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.jamda.2016.12.071","volume":"18","author":"QX Ng","year":"2017","unstructured":"Ng QX, Koh SSH, Chan HW, Ho CYX. Clinical use of curcumin in depression: a meta-analysis. J Am Med Dir Assoc. 2017;18:503\u20138.","journal-title":"J Am Med Dir Assoc"},{"key":"10205_CR30","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1080\/10408398.2019.1653260","volume":"60","author":"L Fusar-Poli","year":"2020","unstructured":"Fusar-Poli L, Vozza L, Gabbiadini A, Vanella A, Concas I, Tinacci S, et al. Curcumin for depression: a meta-analysis. Crit Rev Food Sci Nutr. 2020;60:2643\u201353.","journal-title":"Crit Rev Food Sci Nutr"},{"key":"10205_CR31","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.clnesp.2024.05.017","volume":"62","author":"S Fathi","year":"2024","unstructured":"Fathi S, Agharloo S, Falahatzadeh M, Bahraminavid S, Homayooni A, Faghfouri AH, et al. Effect of curcumin supplementation on symptoms of anxiety: a systematic review and meta-analysis of randomized controlled trials. Clin Nutr ESPEN. 2024;62:253\u20139.","journal-title":"Clin Nutr ESPEN"},{"issue":"1","key":"10205_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6882-6-10","volume":"6","author":"CD Lao","year":"2006","unstructured":"Lao CD, Ruffin MT, Normolle D, Heath DD, Murray SI, Bailey JM, et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med. 2006;6(1): 10. https:\/\/doi.org\/10.1186\/1472-6882-6-10.","journal-title":"BMC Complement Altern Med"},{"key":"10205_CR33","doi-asserted-by":"publisher","first-page":"694","DOI":"10.3109\/1061186X.2016.1157883","volume":"24","author":"W Liu","year":"2016","unstructured":"Liu W, Zhai Y, Heng X, Che FY, Chen W, Sun D, et al. Oral bioavailability of curcumin: problems and advancements. J Drug Target. 2016;24:694\u2013702. https:\/\/doi.org\/10.3109\/1061186X.2016.1157883.","journal-title":"J Drug Target"},{"key":"10205_CR34","doi-asserted-by":"crossref","unstructured":"Karthikeyan A, Senthil N, Min T. Nanocurcumin: a promising candidate for therapeutic applications. Front Pharmacol [Internet]. 2020 [cited 2025 July 15];11:487. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7206872\/.","DOI":"10.3389\/fphar.2020.00487"},{"key":"10205_CR35","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/hdi.12911","volume":"25","author":"G Vafadar-Afshar","year":"2021","unstructured":"Vafadar-Afshar G, Rasmi Y, Yaghmaei P, Khadem-Ansari M-H, Makhdoomi K, Rasouli J. The effects of nanocurcumin supplementation on inflammation in hemodialysis patients: a randomized controlled trial. Hemodial Int. 2021;25:232\u20139.","journal-title":"Hemodial Int"},{"key":"10205_CR36","doi-asserted-by":"crossref","unstructured":"Dende C, Meena J, Nagarajan P, Nagaraj VA, Panda AK, Padmanaban G. Nanocurcumin is superior to native curcumin in preventing degenerative changes in Experimental Cerebral Malaria. Sci Rep [Internet]. 2017 [cited 2025 July 15];7:10062. Available from: https:\/\/www.nature.com\/articles\/s41598-017-10672-9.","DOI":"10.1038\/s41598-017-10672-9"},{"key":"10205_CR37","doi-asserted-by":"publisher","first-page":"158","DOI":"10.2174\/1874471013666191223152658","volume":"16","author":"K Hashemzadeh","year":"2020","unstructured":"Hashemzadeh K, Davoudian N, Jaafari MR, Mirfeizi Z. The effect of nanocurcumin in improvement of knee osteoarthritis: a randomized clinical trial. Curr Rheumatol Rev. 2020;16:158\u201364.","journal-title":"Curr Rheumatol Rev"},{"key":"10205_CR38","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1002\/ptr.7737","volume":"37","author":"H Heidari","year":"2023","unstructured":"Heidari H, Bagherniya M, Majeed M, Sathyapalan T, Jamialahmadi T, Sahebkar A. Curcumin-piperine co-supplementation and human health: a comprehensive review of preclinical and clinical studies. Phytother Res. 2023;37:1462\u201387.","journal-title":"Phytother Res"},{"key":"10205_CR39","doi-asserted-by":"crossref","unstructured":"Pratti VL, Thomas M, Bhoite R, Satyavrat V. Investigating bioavailability of curcumin and piperine combination in comparison to Turmeric Rhizomes: an in vitro study. J Exp Pharmacol [Internet]. 2024 [cited 2025 July 16];16:37\u201347. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC10838102\/.","DOI":"10.2147\/JEP.S427818"},{"key":"10205_CR40","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ejps.2009.02.019","volume":"37","author":"J Shaikh","year":"2009","unstructured":"Shaikh J, Ankola DD, Beniwal V, Singh D, Kumar MNVR. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur J Pharm Sci. 2009;37:223\u201330.","journal-title":"Eur J Pharm Sci"},{"key":"10205_CR41","unstructured":"Lindenmayer JP, Harvey PD, Khan A, Kirkpatrick B. Schizophrenia: measurements of psychopathology. Psychiatr Clin North Am [Internet]. 2007 [cited 2025 July 16];30:339\u201363. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0193953X07000524."},{"key":"10205_CR42","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1097\/00005053-199211000-00007","volume":"180","author":"M Bell","year":"1992","unstructured":"Bell M, Milstein R, Beam-Goulet J, Lysaker P, Cicchetti D. The positive and negative syndrome scale and the brief psychiatric rating scale. Reliability, comparability, and predictive validity. J Nerv Ment Dis. 1992;180:723\u20138.","journal-title":"J Nerv Ment Dis"},{"key":"10205_CR43","doi-asserted-by":"crossref","unstructured":"Pancholi V, Smina TP, Kunnumakkara AB, Maliakel B, Krishnakumar IM. Safety assessment of a highly bioavailable curcumin-galactomannoside complex (CurQfen) in healthy volunteers, with a special reference to the recent hepatotoxic reports of curcumin supplements: A 90-days prospective study. Toxicol Rep [Internet]. 2021 [cited 2024 July 21];8:1255\u201364. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8233102\/.","DOI":"10.1016\/j.toxrep.2021.06.008"},{"key":"10205_CR44","doi-asserted-by":"publisher","first-page":"54","DOI":"10.5414\/CP202076","volume":"53","author":"A Storka","year":"2015","unstructured":"Storka A, Vcelar B, Klickovic U, Gouya G, Weisshaar S, Aschauer S, et al. Safety, tolerability and pharmacokinetics of liposomal curcumin in healthy humans. Int J Clin Pharmacol Ther. 2015;53:54\u201365.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10205_CR45","doi-asserted-by":"crossref","unstructured":"Lee H, Kuwabara Y, Hirose A, Kakinuma T, Baba A, Takara T. Safety evaluation of high bioavailability curcumin in Healthy Japanese Adults: A Randomized, placebo-controlled, double-blind, parallel-group comparison study. Funct Foods Health Dis [Internet]. 2023 [cited 2024 July 21];13:702\u201316. Available from: https:\/\/ffhdj.com\/index.php\/ffhd\/article\/view\/1207.","DOI":"10.31989\/ffhd.v13i12.1207"},{"key":"10205_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jep.2017.07.022","volume":"209","author":"R Bahramsoltani","year":"2017","unstructured":"Bahramsoltani R, Rahimi R, Farzaei MH. Pharmacokinetic interactions of curcuminoids with conventional drugs: a review. J Ethnopharmacol. 2017;209:1\u201312.","journal-title":"J Ethnopharmacol"},{"key":"10205_CR47","doi-asserted-by":"crossref","unstructured":"Appiah-Opong R, Commandeur JNM, van Vugt-Lussenburg B, Vermeulen NPE. Inhibition of human recombinant cytochrome P450s by curcumin and curcumin decomposition products. Toxicology [Internet]. 2007 [cited 2024 July 21];235:83\u201391. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0300483X07001515.","DOI":"10.1016\/j.tox.2007.03.007"},{"key":"10205_CR48","doi-asserted-by":"crossref","unstructured":"Xu Q, Lian H, Zhou R, Gu Z, Wu J, Wu Y, et al. Curcumin and multiple health outcomes: critical umbrella review of intervention meta-analyses. Front Pharmacol [Internet]. 2025 [cited 2025 July 13];16. Available from: https:\/\/www.frontiersin.org\/journals\/pharmacology\/articles\/10.3389\/fphar.2025.1601204\/full.","DOI":"10.3389\/fphar.2025.1601204"},{"key":"10205_CR49","doi-asserted-by":"crossref","unstructured":"Murray AJ, Rogers JC, Katshu MZUH, Liddle PF, Upthegrove R. Oxidative stress and the pathophysiology and symptom profile of Schizophrenia spectrum disorders. Front Psychiatry [Internet]. 2021 [cited 2024 July 21];12. Available from: https:\/\/www.frontiersin.org\/journals\/psychiatry\/articles\/10.3389\/fpsyt.2021.703452\/full.","DOI":"10.3389\/fpsyt.2021.703452"},{"key":"10205_CR50","doi-asserted-by":"crossref","unstructured":"Moghaddam AH, Maboudi K, Bavaghar B, Sangdehi SRM, Zare M. Neuroprotective effects of curcumin-loaded nanophytosome on ketamine-induced schizophrenia-like behaviors and oxidative damage in male mice. Neurosci Lett [Internet]. 2021 [cited 2024 July 21];765:136249. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0304394021006285.","DOI":"10.1016\/j.neulet.2021.136249"},{"key":"10205_CR51","doi-asserted-by":"crossref","unstructured":"Parasuraman S, Zhen KM, Banik U, Christapher PV. Ameliorative effect of curcumin on Olanzapine-induced obesity in Sprague-Dawley rats. Pharmacogn Res [Internet]. 2017 [cited 2024 July 21];9:247\u201352. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5541480\/.","DOI":"10.4103\/pr.pr_8_17"},{"key":"10205_CR52","doi-asserted-by":"publisher","first-page":"558","DOI":"10.3389\/fnins.2017.00558","volume":"11","author":"Z Liu","year":"2017","unstructured":"Liu Z, Cui C, Xu P, Dang R, Cai H, Liao D, et al. Curcumin activates AMPK pathway and regulates lipid metabolism in rats following prolonged clozapine exposure. Front Neurosci. 2017;11:558.","journal-title":"Front Neurosci"}],"container-title":["Psychiatric Quarterly"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11126-025-10205-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11126-025-10205-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11126-025-10205-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T15:50:37Z","timestamp":1783007437000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11126-025-10205-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,18]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10205"],"URL":"https:\/\/doi.org\/10.1007\/s11126-025-10205-y","relation":{},"ISSN":["0033-2720","1573-6709"],"issn-type":[{"value":"0033-2720","type":"print"},{"value":"1573-6709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,18]]},"assertion":[{"value":"19 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human Ethics and Consent to Participate declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}